Health Care

Scynexis announces public offering of common stock, warrants

“2020 represents what will be a significant year for Scynexis as it is rich in key milestones, and these proceeds provide us greater financial flexibility as we continue to advance our clinical programs and prepare for our first NDA submission for the treatment of vulvovaginal candidiasis, expected in the second of half of 2020,” Eric Francois, chief financial officer of Scynexis told NJBIZ.

Read More »